- Home
- RIGL vs BMRC Comparison
RIGL vs BMRC Comparison
Compare RIGL & BMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- BMRC
- Stock Information
- Founded
- RIGL 1996
- BMRC 1989
- Country
- RIGL United States
- BMRC United States
- Employees
- RIGL N/A
- BMRC N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- BMRC Major Banks
- Sector
- RIGL Health Care
- BMRC Finance
- Exchange
- RIGL Nasdaq
- BMRC Nasdaq
- Market Cap
- RIGL 335.5M
- BMRC 365.9M
- IPO Year
- RIGL 2000
- BMRC N/A
- Fundamental
- Price
- RIGL $41.50
- BMRC $24.25
- Analyst Decision
- RIGL Buy
- BMRC Buy
- Analyst Count
- RIGL 5
- BMRC 4
- Target Price
- RIGL $38.20
- BMRC $26.25
- AVG Volume (30 Days)
- RIGL 845.0K
- BMRC 113.7K
- Earning Date
- RIGL 08-05-2025
- BMRC 07-28-2025
- Dividend Yield
- RIGL N/A
- BMRC 4.36%
- EPS Growth
- RIGL N/A
- BMRC N/A
- EPS
- RIGL 5.43
- BMRC 0.43
- Revenue
- RIGL $267,921,000.00
- BMRC $93,409,000.00
- Revenue This Year
- RIGL $14.41
- BMRC $61.05
- Revenue Next Year
- RIGL $15.97
- BMRC $10.99
- P/E Ratio
- RIGL $7.64
- BMRC $56.09
- Revenue Growth
- RIGL 105.62
- BMRC 59.35
- 52 Week Low
- RIGL $12.00
- BMRC $19.11
- 52 Week High
- RIGL $43.72
- BMRC $27.11
- Technical
- Relative Strength Index (RSI)
- RIGL 86.20
- BMRC 62.01
- Support Level
- RIGL $38.43
- BMRC $22.71
- Resistance Level
- RIGL $41.25
- BMRC $23.22
- Average True Range (ATR)
- RIGL 2.50
- BMRC 0.65
- MACD
- RIGL 0.89
- BMRC 0.14
- Stochastic Oscillator
- RIGL 89.85
- BMRC 95.02
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.